Perspective Therapeutics (NYSEAMERICAN:CATX) Reaches New 1-Year High at $1.90

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as 1.90 and last traded at 1.84, with a volume of 3917500 shares traded. The stock had previously closed at 1.83.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. B. Riley increased their target price on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st.

Perspective Therapeutics Stock Up 0.5 %

The company has a market cap of $1.08 billion, a P/E ratio of -18.40 and a beta of 1.43. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Perkins Capital Management Inc. purchased a new stake in Perspective Therapeutics in the third quarter valued at approximately $731,000. HighTower Advisors LLC bought a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $314,000. Taylor & Morgan Wealth Management LLC grew its position in Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after acquiring an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Perspective Therapeutics in the third quarter valued at $42,000. Finally, RIA Advisory Group LLC raised its position in Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares in the last quarter. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.